NASDAQ:PCRX

Pacira BioSciences Stock Forecast, Price & News

$63.25
+0.04 (+0.06 %)
(As of 05/7/2021 04:30 PM ET)
Add
Compare
Today's Range
$62.67
$64.15
50-Day Range
$61.48
$71.77
52-Week Range
$39.35
$80.00
Volume448,818 shs
Average Volume480,297 shs
Market Capitalization$2.78 billion
P/E Ratio22.27
Dividend YieldN/A
Beta1.27
30 days | 90 days | 365 days | Advanced Chart
Receive PCRX News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:PCRX
CUSIP69512710
Phone973-254-3560
Employees624
Year FoundedN/A

Sales & Book Value

Annual Sales$421.03 million
Cash Flow$1.49 per share
Book Value$8.51 per share

Profitability

Net Income$-11,020,000.00

Debt

Price-To-Earnings

Miscellaneous

Market Cap$2.78 billion
Next Earnings Date8/5/2021 (Estimated)
OptionableOptionable

Headlines

See More Headlines
Pacira BioSciences logo

About Pacira BioSciences

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a bupivacaine liposome injectable suspension, administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Parsippany, New Jersey.

MarketRank

Overall MarketRank

1.92 out of 5 stars

Medical Sector

89th out of 2,041 stocks

Pharmaceutical Preparations Industry

33rd out of 769 stocks

Analyst Opinion: 2.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 4.4 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Pacira BioSciences (NASDAQ:PCRX) Frequently Asked Questions

Is Pacira BioSciences a buy right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacira BioSciences in the last year. There are currently 4 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Pacira BioSciences stock.
View analyst ratings for Pacira BioSciences
or view top-rated stocks.

What stocks does MarketBeat like better than Pacira BioSciences?

Wall Street analysts have given Pacira BioSciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Pacira BioSciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Pacira BioSciences' next earnings date?

Pacira BioSciences is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Pacira BioSciences
.

How were Pacira BioSciences' earnings last quarter?

Pacira BioSciences, Inc. (NASDAQ:PCRX) issued its quarterly earnings results on Monday, May, 3rd. The company reported $0.53 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.64 by $0.11. The firm earned $119 million during the quarter, compared to analyst estimates of $119.23 million. Pacira BioSciences had a trailing twelve-month return on equity of 10.71% and a net margin of 29.95%. The business's revenue was up 12.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.53 earnings per share.
View Pacira BioSciences' earnings history
.

How has Pacira BioSciences' stock price been impacted by Coronavirus (COVID-19)?

Pacira BioSciences' stock was trading at $35.19 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PCRX shares have increased by 80.1% and is now trading at $63.36.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for PCRX?

12 Wall Street analysts have issued 1 year price targets for Pacira BioSciences' shares. Their forecasts range from $48.00 to $94.00. On average, they expect Pacira BioSciences' stock price to reach $76.75 in the next twelve months. This suggests a possible upside of 21.1% from the stock's current price.
View analysts' price targets for Pacira BioSciences
or view top-rated stocks among Wall Street analysts.

Who are Pacira BioSciences' key executives?

Pacira BioSciences' management team includes the following people:
  • Mr. David M. Stack, Chairman & CEO (Age 71, Pay $1.47M)
  • Mr. Charles A. Reinhart III, CPA, M.B.A., Chief Financial Officer (Age 60, Pay $637.22k)
  • Ms. Kristen Williams, Chief Admin. Officer & Sec. (Age 47, Pay $727.97k)
  • Dr. Roy Winston, Chief Clinical Officer (Age 60, Pay $647.06k)
  • Mr. Max Reinhardt, Pres of Rest of World (Age 50, Pay $619.19k)
  • Ms. Lauren Bullaro Riker, Principal Accounting Officer & VP of Fin. (Age 42)
  • Mr. Charles Laranjeira, Chief Technical Officer (Age 55)
  • Susan Mesco, Head of Investor Relations
  • Mr. Richard Kahr, VP of HR
  • Mr. Robert J. Weiland, Sr. VP of Alliance Management (Age 61)

What is Dave Stack's approval rating as Pacira BioSciences' CEO?

54 employees have rated Pacira BioSciences CEO Dave Stack on Glassdoor.com. Dave Stack has an approval rating of 45% among Pacira BioSciences' employees. This puts Dave Stack in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Pacira BioSciences' key competitors?

What other stocks do shareholders of Pacira BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira BioSciences investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), Skyworks Solutions (SWKS), AbbVie (ABBV), Pfizer (PFE), QUALCOMM (QCOM), Exelixis (EXEL) and Tesla (TSLA).

What is Pacira BioSciences' stock symbol?

Pacira BioSciences trades on the NASDAQ under the ticker symbol "PCRX."

Who are Pacira BioSciences' major shareholders?

Pacira BioSciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (4.76%), Great Lakes Advisors LLC (0.49%), Zweig DiMenna Associates LLC (0.42%), British Airways Pensions Investment Management Ltd (0.38%), Rhumbline Advisers (0.29%) and MESIROW FINANCIAL INVESTMENT MANAGEMENT Equity & Fixed Income (0.27%). Company insiders that own Pacira BioSciences stock include Andreas Wicki, Charles A Reinhart III, Charles Anthony Laranjeira, David M Stack, Dennis Mcloughlin, John P Phd Longenecker, Kristen Marie Williams, Laura Brege, Lauren Bullaro Riker, Max Reinhardt, Paul J Hastings, Richard Scranton and Roy Winston.
View institutional ownership trends for Pacira BioSciences
.

Which major investors are selling Pacira BioSciences stock?

PCRX stock was sold by a variety of institutional investors in the last quarter, including Tributary Capital Management LLC, MESIROW FINANCIAL INVESTMENT MANAGEMENT Equity & Fixed Income, Los Angeles Capital Management LLC, State of New Jersey Common Pension Fund D, State of Alaska Department of Revenue, Texas Permanent School Fund, Fisher Asset Management LLC, and Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have sold Pacira BioSciences company stock in the last year include Andreas Wicki, Charles A Reinhart III, Charles Anthony Laranjeira, David M Stack, Kristen Marie Williams, Laura Brege, Lauren Bullaro Riker, Max Reinhardt, Paul J Hastings, and Roy Winston.
View insider buying and selling activity for Pacira BioSciences
or view top insider-selling stocks.

Which major investors are buying Pacira BioSciences stock?

PCRX stock was purchased by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Scout Investments Inc., Braun Stacey Associates Inc., Hodges Capital Management Inc., Victory Capital Management Inc., Gradient Investments LLC, Zweig DiMenna Associates LLC, and British Airways Pensions Investment Management Ltd.
View insider buying and selling activity for Pacira BioSciences
or or view top insider-buying stocks.

How do I buy shares of Pacira BioSciences?

Shares of PCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pacira BioSciences' stock price today?

One share of PCRX stock can currently be purchased for approximately $63.36.

How much money does Pacira BioSciences make?

Pacira BioSciences has a market capitalization of $2.79 billion and generates $421.03 million in revenue each year. The company earns $-11,020,000.00 in net income (profit) each year or $0.86 on an earnings per share basis.

How many employees does Pacira BioSciences have?

Pacira BioSciences employs 624 workers across the globe.

What is Pacira BioSciences' official website?

The official website for Pacira BioSciences is www.pacira.com.

Where are Pacira BioSciences' headquarters?

Pacira BioSciences is headquartered at 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054.

How can I contact Pacira BioSciences?

Pacira BioSciences' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-254-3560 or via email at [email protected]


This page was last updated on 5/7/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.